Investigational CRISPR-Cas9-edited T cells for metastatic colorectal cancer treatment: Clinical insights for future development
Abstract
Significant efforts in immunobiology and tumor cell biology have led to important advances in incorporating immunotherapy into treatment for patients with metastatic colorectal cancer (CRC) (mCRC). However, these successes have for the most part been achieved in the relatively small number of patients with tumors harboring a mismatch repair deficiency1 resulting in microsatellite instability-high (MSI-H) disease; notably, in CRC this number is lowest (∼5%) in the metastatic setting than in earlier stages (∼10%–15%).
Fields of Study & Subjects
CAR-T cell therapy research
Cancer Immunotherapy and Biomarkers
CRISPR and Genetic Engineering
Publication details
- Journal / source
- Molecular Therapy Oncology
- Volume
- 34
- Issue
- 1
- Pages
- 201139–201139
- Publication date
- 16 February 2026
- Language
- EN